Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Surgical Science Sweden, Audiocast, Q3'26

By Inderes11/12/2026, 10:00 AM
Surgical Science Sweden

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Tom Englund
00:00 - 10:55

Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I will start with the highlights of the quarter and what we are seeing in our markets. Then Anna will take you through the financials in more detail. And after that, we will open the floor for questions. Quarter three was another step in the right direction for Surgical Science. If I should summarize the quarter in one sentence, it would be that we are on the right track with profitability. And our strategy is delivering. Our adjusted EBIT margin was 15%, which is in line with our financial targets. The gross margin improved by three percentage points to 68% and cash flow was strong. Sales were stable against a strong comparison quarter last year and over the first nine months. We are growing. Growth is, though not yet at our target level, and we have been open about that for 2026. 2027 is the year we expect to reach our financial targets, with stable license revenue and a 15% margin. With our current margins, we are clearly approaching our financial targets. The most important story is Educational Products, and US sales in the US this quarter grew by almost 50% compared with last year, and the Americas region as a whole grew by 30%. Earlier this year, I talked about the hesitation in the US market and long purchasing decisions, and since then we have changed the way we work. We have strengthened our sales organization, we have raised our prices, and what we are seeing now is the effect of those decisions. It is not due to one single deal, but rather a broad-based improvement, and it has been building quarter over quarter. We also see a better funding climate at the state level. While federal funding is still held back by budgetary and some political uncertainty. Ultrasound is the other bright spot in the report, with a growth of 14%. Demand is stable, both from our traditional customers and from POCUS, point-of-care ultrasound. Ultrasound is used as a diagnostic tool at the bedside. Women's health remains a prioritized area, and this quarter we added a new breast ultrasound module to Ultrasound Mentor. Which brings me to Aeris. Our new ultrasound simulator, which we launched at the end of September at EUSEM, the European Emergency Medicine Congress in Paris with more than 2,700 physicians. Why is this important? Emergency medicine is one of the five simulation areas that our strategy is built upon. POCUS is one of the fastest-growing uses of ultrasound. The need for examinations is growing much faster than the number of sonographers. So more and more emergency physicians need to learn to scan themselves. And that is exactly what Aeris is built to train. The reception at USM for Aeris was very positive. Aeris accounted for the majority of the customer leads that we generated at the congress, and the first deliveries have started now in quarter four. And earlier this week, Aeris won the Best of Innovation Award in the Educational Technology category at CES, the world's largest consumer technology show taking place in Las Vegas in January. We're extremely proud of that, and it's a great recognition for the team behind it. In February 2025, we concluded the acquisition of Intelligent Ultrasound, and we have become the unparalleled world leader in ultrasound simulation. We are very happy with this acquisition, and we are continuously realizing the strategic synergies that we planned as the rationale for the acquisition. The new Aeris product is a result of the combined tech stack from Intelligent Ultrasound and Surgical Science. And we have plans to launch many more exciting products within this space. During the quarter, we also launched a new version of our Mentor Learn training platform and new basic exercises for Robotics Express, and our recurring service revenue keeps building. It grew by 15%, and September was the strongest service month so far this year. Before I move on to industry, I would like to mention a few words on EMEA, which was down in this quarter. The comparison quarter included several large tenders, especially in Poland, that were not repeated this year, and that is the nature of tender markets. They come in large steps. So, over the year as a whole. EMEA is clearly up, and we have a positive view of demand for the coming quarter and next year in APAC. China was weaker. China is structurally challenging right now for foreign companies. And that is why we have established our own entities in Hong Kong and China this quarter. It's a long-term investment in being closer to our customers, and we're already seeing the early signs that this investment is starting to pay off. In robotics, license revenue grew by 16% and it has stayed at a high level all year. For me, the most important point is not the number in a single quarter. License revenue will always vary between quarters. It is that the revenue comes from several of our robotics customers. The customer base is broadening, and we are less dependent on any single customer than we were a year ago. Our collaboration with Intuitive continues, and the impact from their adjusted digital strategy has been smaller than we first estimated. We also saw increased activity and sales from Asian robotics manufacturers, which builds the potential for future license revenue. Our new suturing exercises for robotics, Express, launched at SRS this summer, have been very well received, and we deepened our partnerships with several robotics associations around validation and certification in robotic surgery. Let me say a few words about the market because it is moving in our direction. Intuitive continues to grow strongly, with da Vinci procedures up 14% and an installed base of more than 12,000 systems. At the same time, the market is broadening. Two of our customers, Medtronic and Cornerstone Robotics, have entered into a strategic partnership that will significantly increase the pace of commercialization, and Medtronic expects Hugo to reach 250 installed systems by April of next year. After the quarter, Stryker invested in CMR Surgical, and Digital Motion raised new funding to grow in the US. More players have the capital to bring their robots to market, and healthcare is financing robotic surgery more aggressively. We also see positive signs that authorities are starting to set requirements for simulation. The FDA is now updating its guidelines for robotic surgery. Every new platform and every new installation needs trained surgeons. That is the basis for our license revenue. And we are convinced that simulation will be a central element in every robotics company's digital offering going forward. Medical device simulation had a weaker quarter. Last quarter, I said I expected this business to grow, and the third quarter did not show that. I want to be clear about that. This business depends on when customers place their often large orders. And the timing didn't fall well in this quarter. But the underlying demand is still good. More than 70% of our customers in our active development projects are repeat clients, and the projects were largely delivered according to plan. The lead indicators remain positive. In emergency medical simulation, we took an important step. We delivered the hardware in the project for a defense ministry in Southeast Asia, and in September, the customer's final acceptance test was carried out on the site with good results. Delivering a project of this size and complexity on time and with the required quality gives us a strong reference as we approach similar opportunities now in several other countries. The gross margin improvement that we see in the quarter is the result of a number of different factors. More license revenue in the mix. More direct sales in the US. The price increases that we have carried out, and also the cost management programs that we have started in production. And we have achieved these improvements despite the strong Israeli shekel, higher component prices, and the lower-margin hardware delivery. So the underlying improvement is really positive to see. At the same time, I want to be open about that. There are still parts of the business where profitability is not good enough, and some of that is of a non-recurring nature and some is more structural. And we are working on improving this step by step. Looking ahead. September was a strong month in several regions, and we are entering the fourth quarter with a good order backlog and pipeline within Educational Products. Let me step back to where we are going. We are almost one year into the strategy that we presented at our Capital Markets Day last December. We focus on five simulation areas: minimally invasive surgery. Ultrasound simulation, emergency medicine simulation, robotic surgery simulation, and medical device simulation, all with low to very low penetration. And we can see that the work now in these areas is delivering clear results, both financially and operationally. Our focus going forward is growth. We have a market-leading position in medical simulation, recurring revenue that keeps growing, no debt, and a strong balance sheet. Our vision is that all healthcare personnel are trained and certified in a simulated environment before they perform procedures on patients. Demand is driven by aging populations, increasing complexity in healthcare, and higher standards for patient safety. And the combination of digitalization and AI offers significant new opportunities for us. I'm confident in our ability to continue generating profitable growth and to reach our financial targets. Thank you. And with that, I'll hand over to Anna.

Anna Ahlberg
10:57 - 27:14

Thank you, Tom. We will start with revenues. And again, the third quarter was another solid quarter for us. Sales came in at 260 million SEK. That was down 1% both in SEK and also on an FX-adjusted basis. But it is again worth remembering that Q3 last year was a really strong quarter, partly also because of delayed orders from Q2 2025. So that quarter had a growth of almost 14% and a tough, tough comparison. And for the first nine months, sales are up 4%, or 5% in local currencies, at 750 million SEK. Then, for the first nine months, the average US dollar rate, which is of very high importance to us. That was 9.39 compared to 9.95 last year. So it was down significantly for this quarter. As such, the currency effect on sales was neutral. However, on the cost side, the Israeli shekel, which is very important for us, has continued to be strong against the US dollar. And that affects our margins negatively. Looking at the business areas, the split was 54% for Educational Products and 46% for Industry in this quarter. Educational Products was then up 1% or 2% in local currencies. And for the first nine months, revenue was up 8%. As Tom mentioned, the large positive within this area this quarter and also last quarter is the US sales, which were up 49% compared with Q3 last year and 19% if we compare to Q2. And that quarter was, in turn, stronger than any other quarter in 2025. And the Americas region as a whole grew by 30%. EMEA was down 31%, as Tom mentioned; this is primarily because of several large orders in the comparison quarter, particularly in Poland, but also in, for example, Portugal and Romania. They were not repeated. However, for this quarter, we saw strong numbers in the Netherlands and the Czech Republic. And again, sales per country. They do vary a lot between periods depending on when large procurements take place. But EMEA has been very strong this year. And for the first nine months, it is still up by 28%. And we do have a positive view on demand for this region also going forward. APAC was down a bit again, mainly due to lower sales in China. Japan was stronger this quarter, as Tom mentioned. We did commence operations in our new companies in Hong Kong and in China during the quarter. Our simulation area, Ultrasound, continues to grow by 14%. This whole year has been very positive for this area. We also see a bright outlook with new products such as Aeris, while robotic surgery increased by close to 20%, whereas minimally invasive surgery and medical device, including emergency medicine, decreased. Industry was down 4% or 5% in local currencies, license revenues increased 16% to 76 million, while simulator sales to medical device companies were weaker. And we can see that on this. On the next slide, when we look at our revenue streams, license revenues account for 29% of our total revenues this quarter. They were 25% in Q3 2025, and for the first nine months, license revenues were up 10% to almost 230 million, or 30% of sales, a bit more than 2025 when it was 29%. So license revenues have stayed at a good level throughout the year. And this quarter too. Then they came from several of our robotics customers. We also saw increased activity from robotics manufacturers during the quarter, as Tom talked about, which creates potential for future license revenue. And regarding Intuitive, as we said in the Q2 report, we assessed the total revenue loss for 2026, attributable to the memorandum of understanding to be less than the range of 60 to 90 million. We indicated this earlier. So. So this still stands, even though it is still too early to say how this will develop going forward. Simulator sales as a whole, meaning both Educational Products and Industry, were down 7% to 143 million Swedish kronor. Simulator sales were flat. So the decrease comes from Industry, where sales of simulators to medical device companies were 23 million. As we said before, this business is lumpy. It depends on when customers place their often large orders. Underlying demand is good, and we have a high share of recurring customers. And for the first nine months, simulator sales are up 3%. In total, it was up 9% and then down 22%. Development revenues were 16 million. That is slightly higher than Q2, but weaker than Q3 last year. And regarding the project for the Defense Ministry in the Southeast Asian country, the hardware was delivered during this quarter, and that was almost 10 million in revenue, meaning that development revenues were 1.7 million. And the project is now, as we heard, largely completed; we have approximately 4.5 million remaining. And we expect to recognize that in Q4. Service revenues were really strong for the quarter, up 15%, and September was a really strong month for us. Moving then on to costs and margins. Our gross margin for the quarter was 68%. Three percentage points higher than in the comparison quarter. And here we have both positive and negative effects. Tom mentioned them. Let me go through them again. On the positive side, there is a higher share of license revenues. That is positive for the gross margin. Also, the share of direct sales, which is primarily attributable to the US, was higher. That was higher. And our price increases continue to have an effect. We are also seeing results from the cost management programs we have started in production, which is also positive. And then on the negative side, the hardware delivery for the defense project that had a lower margin and also currency effects have had a negative impact for the quarter of approximately 1.3 percentage points. For the first nine months, the gross margin was 68%. And here we see a negative currency effect of 1.1 percentage points. Sales costs were 21% of sales, or 55 million. Here in this quarter. We had an item of just below 3 million of a more occasional nature that is related to commissions to distributors. And this varies depending on the country in which the sales take place. We have this set up for a few countries, and also if we compare to Q2, we did not record any refunds of US customs duties this quarter. We did that in Q2, and we will also have refunds in Q4. Admin costs were 8% of sales, as in Q2. The costs include costs for the work on the change of listing to the Nasdaq main market, and it was exactly the same amount as in Q2, 1.1 million. We still expect this to take place next year. We also had a non-recurring positive item of just below 3 million related to IFRS 16 within admin, and the corresponding item is then in the finance net negative of the same amount. So this is a reclassification. R&D costs were 24% of sales, totaling 63 million. We capitalized approximately 10 million. It was a bit higher than last year, but 3.3 million lower if we compare to Q2. Also during this quarter, we started to amortize a few larger projects that we had been capitalizing on and that were now finished. And that also increased our costs on this line by approximately 1.4 million. Other operating income and operating costs include a lot of revaluation items. And this had a smaller negative impact this quarter of 4 million SEK. The revaluations themselves. They were just below 3 million. And then we also have the warrant programs that we have here. And that was just about 1 million for the quarter. So following this, our EBIT or operating profit for the quarter was 32 million, a margin of 12%. If we adjust for FX effects, EBIT for the quarter was 39 million, or 15%. And for the first nine months, we also had a margin of 12% and currency-adjusted. That was 16%. Looking at our organization, we were 324 people at the end of Q3. That is four fewer than at the end of Q3 last year, and five more than at the end of Q2 compared with last year. The decrease is in the US and UK, mainly related to the restructuring of the sales force following the acquisition of Intuitive. While we have added a few people in Israel as well as in Sweden, and since we have also started operations in our new companies in Hong Kong and China, this is also a region where we are growing. We are adding a few people. So adjusted EBIT, then EBIT, excluding amortization on surplus values related to our acquisitions. So we have our financial goal of 15%. The result for the quarter was 38 million SEK. That is an increase of 15%, a margin of 15%, and also in line with our financial target of at least 15%. If we adjust for FX effects the same way as we do for Adjusted EBIT, the margin was 17%. And for the first nine months, the corresponding figures were 14% or FX-adjusted 18%. So, a clear improvement for our adjusted EBIT. And as we have said, profitability is now essentially in line with our target, while growth is not yet at the target level, which is in line with our assessment that we made for this year. Finance and taxes. Primarily, this includes interest income on bank deposits, reevaluations, and IFRS 16. As I mentioned before, there was this reclassification item of 2.7, which is also in the finance net. Net profit was 34 million SEK. We had a low tax expense this quarter that was due to the final tax return in our Israeli company, which resulted in a positive adjustment for the quarter. And then affecting the effective tax rate is also the fact that we have non-deductible amortization in our P&L. And for the quarter, they were approximately 6 million SEK. Cash flow was good. Operating activities were 43 million compared with a slight negative for Q3 last year. Working capital was slightly negative at minus 7 million SEK. And both inventories and accounts receivable increased a bit for the first nine months. Then cash flow from operating activities is positive 123 million. We also have positive cash flow from working capital for the period. And as you can see from the gray line there, accounts receivable in relation to sales continue to be at a good level. Investing activities for the quarter are mainly in development costs. We did invest in our new production facility in Tel Aviv, but that started and the facilities were commissioned at the end of Q2. That in total is an investment of 21 million, of which 14 million is in 2026. At the end of the quarter, our cash position was 675 million SEK.

Tom Englund
27:17 - 28:15

Thank you, Anna. So to wrap up before the questions, quarter three was another step in the right direction for Surgical Science. Sales were stable against a strong comparison quarter. The gross margin improved to 68%. Adjusted EBIT grew 15% to 38 million SEK with a 15% margin. License revenue grew 16% and operating cash flow was strong. We have strong momentum in the US ultrasound business with the launch of Aeris, license revenue from a broadened robotics customer base, and an important delivery in emergency medical simulation. And we are entering quarter four with a good order backlog and pipeline, with an adjusted EBIT margin of 15%. We are in line with our financial targets. We're firm believers that simulation will become a central part of how healthcare trains its professionals, and we intend to lead that shift. And with that, we open the floor for questions.

Operator
28:16 - 28:34

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Christian Lee from Pareto Securities. Please go ahead.

Christian Lee
28:37 - 29:12

Good morning, and thank you for taking my two questions. My first is regarding the Intuitive related license revenue that you assess will come in below the 60 to 90 million range. But the message in this report appears to be more cautious. As you say, it is too early to say how this development will continue. So, have you received any changed response from end customers? And why have you not been able to narrow the range with less than two months left of the year?

Tom Englund
29:15 - 30:09

Yeah. Hi Christian. So the license revenue from Intuitive, we have said that we see a lower impact than the 60 to 90 million that we indicated earlier this year. We stand by that. We stand by that statement also. Now for quarter four. We have no new information to change that statement in any way. What I think is very positive here is that, with the broadened customer base that we see and the license revenue coming in from many different customers, the impact of one particular customer is, of course, lower in the total revenues. Which reduces the risk. So that is very positive. But we don't have any further comments exactly on the future development of the license revenue. Intuitive license. Revenues.

Anna Ahlberg
30:10 - 30:31

And I think Christian, also your comment around that. It is too early to say. It was also part of the discussion. Now we. Subscriptions that are renewing, etc. . That was the case in the last quarter. And that is still too early to say exactly how that will develop. So it is more in that context.

Christian Lee
30:34 - 30:54

Okay, great. Thank you. My second question is regarding Educational Products that had a solid quarter, growing year-over-year despite the tough comps, and posting its highest ever Q3 sales. Given that you flagged volatility between quarters, how should we think about the fourth quarter?

Tom Englund
30:56 - 32:24

We mentioned a positive order pipeline and a positive outlook for quarter four in my speech and presentation, as well as in the CEO letter. We look positively on the future for Educational Products. I think structurally, it is extremely positive to see the strength of the US market and the growth that we see in the US market. It has been growing. Now, it's not just this third quarter that's been growing. It has been growing for the last three quarters tremendously, as Anna pointed out. I think that we have a fantastic position to grow Educational Products both in the US, but also globally. Even further, we have a fantastic product offering that we can offer more broadly to customers. Aeris is a good example of that. We are also continuously making changes to become more efficient in sales and meet more customers. There is a lot of innovation and development happening on the sales side. That will also drive growth. And then thirdly, there is an inherent market growth within the Educational Products business. We can discuss it a little bit back and forth, but it is definitely much more than 10%, probably closer to 15% to 20%. And we can affect that market growth also by the actions and the products that we take. So. So we see that we have nowhere near saturated the market within Educational Products.

Christian Lee
32:26 - 32:30

Okay. That's very clear. Thank you very much. I will jump back to the Q&A. Q.

Operator
32:33 - 32:37

The next question comes from Simon Larsen from Danske Bank. Please go ahead.

Simon Larsen
32:38 - 32:58

Yes. Good morning. Good morning. Also, from my end, I was curious about the simulator sales within the industry OEM segment because it has been muted for quite some quarters now. Do you foresee any larger projects going live in the near or mid-term that might shift the trajectory that we have seen so far this year?

Tom Englund
33:00 - 34:18

Hi, Simon. We are not happy with the development of simulator sales in the industry segment, nor with the development of revenues for the industry segment either. But as you know, it is a small P&L, a relatively small revenue, and it can fluctuate, as these projects are big, both the simulator orders that we get and also the development projects that we do. So it can be very lumpy. And you know that we have spoken about that a lot, right? Previously, we have had big replacement product programs from some of our customers that have led to large purchases of simulators. And for some quarters now, we have not had those same effects. But I am very clear about that. We are working on large projects and development projects that will ultimately lead to strong simulator sales. I think that it is very important that we provide good customer value in the products that we deliver and that we deliver on time. I wrote in the CEO letter that we feel we deliver on these projects and customers are generally happy. So it's more of an effect of lumpiness when it comes to the simulator sales. Am I happy about this quarter? No, not really, but I think we are executing in the right direction.

Simon Larsen
34:20 - 34:45

Yep. Very good. And then my final question, at least for now, is on the balance sheet, as we all know you have a very significant net cash position. And First North is allowing for buybacks here, I think from the 5th of December. And you also, of course, are aiming to head to the Small Cap main market. Should we expect some buybacks already this fiscal year, or what do you believe? What is your assessment of that?

Anna Ahlberg
34:47 - 35:13

Yeah. Yes. December 5th is the date from when we also on First North can do buybacks with a mandate there. I mean, that is a structured process that has to be decided by the board, and that will then be communicated if and when there is a decision from the board on that.

Simon Larsen
35:13 - 35:18

Oh, okay. So there is no decision allowing you to start on the 5th as of now.

Anna Ahlberg
35:20 - 35:20

No.

Simon Larsen
35:21 - 35:23

No. Okay. Very good. Thank you.

Operator
35:26 - 35:39

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Maria Carlson-Osipova from AB Carnegie. Please go ahead.

Maria Carlson-Osipova
35:40 - 36:04

Hi. Good morning. Tom. Good morning, Anna. So my colleagues have asked a lot of good questions, and I want to discuss the point you mentioned on the investor call earlier today regarding the potential to further improve gross margins through additional efficiency measures. Did I understand that correctly? And if you could please elaborate more on that in that case.

Tom Englund
36:06 - 37:55

Yeah. Hi Maria. So there is definitely room for further gross margin improvements. And even though we see a good trend in this quarter compared to Q3 of last year, we also point out that there are several items that work negatively and impact our gross margin development. So I think that there are a lot of things that we can do and that we are doing. An increased license mix is an obvious one, right? And that is well, not small. It is a contribution to the gross margin improvement this year. But then on the simulator side, there are many things that we can do around pricing, product mix, and ensuring that we have a high and attractive gross margin on the new products that we launch. If we also then on top of that, have a higher share of direct sales in the US and lower discounts for those sales, that also works in our favor. And then there's a lot we can do on the cost side; we have already, as I mentioned, launched cost efficiency programs and cost savings programs within operations. And we have not yet seen the full effects of those. And this is, of course, not work that you just do for one or two quarters. It is an ongoing focus. And then I think that the last part is also the volume, meaning that as the P&L grows, as the revenue grows, the fixed costs in production will be allocated towards more units. And that will also improve gross margins here. So volume growth for simulators is an important component to grow gross margins further. So there is plenty of work already started. We are seeing some effects, and that is very promising and satisfying. But there is a long way to go.

Maria Carlson-Osipova
37:59 - 38:29

All right. Thank you for that. And my second question would be on the ultrasound segment. You talk quite a bit about that in the report. And also now in the presentation. And it's very encouraging to see. But as for Aeris, if first deliveries started now in Q4, how should we think about that going forward? When should we expect this product to begin making a more meaningful contribution to sales? And also, who are the primary customer segments for Aeris for you?

Tom Englund
38:29 - 40:59

Yeah. We think of Aeris as an exciting product, both because of the performance and because it is very accessible and easy to use. It has a clear customer value for point-of-care ultrasound, the segment for which it is designed, which is ultrasound simulation at the bedside, a very big and growing segment within ultrasound. It is also cost-efficient in that it has a lower price than traditional ultrasound simulators. It is definitely an exciting new product and an exciting new segment for us; in terms of the sales cycles for this product, what we have seen is a tremendous influx of leads for Aeris in this quarter that are now materializing into firm orders. The lead-to-order process can be quite long, even for a product that is less pricey than the traditional simulators, in that our customers need to acquire and get budget approval for the purchase; it can range from weeks to months, but we feel confident that Aeris will start being shipped in significant numbers in the first quarter of next year. And it is also already going to ship here in quarter four. But we do not expect Aeris to have a huge positive impact on our sales in this quarter, quarter four, but rather an increasing positive impact throughout the year of next year. Then I think it is very interesting to move into the ultrasound segment because it is a segment that has a lot of potential trainees. We are speaking about trainees in the hundreds of thousands, or even in the millions, that need to learn ultrasound, especially point-of-care ultrasound. So this is an exciting step into a significantly larger market with a significantly bigger TAM. And this is about what we discussed at the Capital Markets Day about a year ago, where we want to broaden our different target segments and stand on more legs than just the two we traditionally stood on. And now we have five distinct segments where ultrasound is going to contribute a quite important part of the total revenue of Surgical Science, I believe, in the coming years.

Maria Carlson-Osipova
41:02 - 41:06

All right. Thank you so much for that answer. That will be all for me.

Unknown 1
41:07 - 41:07

Thank you.

Operator
41:10 - 41:17

There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions or closing comments.

Tom Englund
41:21 - 41:38

We don't have any more questions as I see it. So with that, I would like to conclude the meeting and thank everybody for your active participation and questions, and I look forward to meeting you here in three months' time again. Thank you.

Anna Ahlberg
41:38 - 41:39

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…